Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-grade serous ovarian cancer, drawn from the whole corpus: 19 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No screening test lowers mortality.
Homologous recombination proficient tumours gain little from PARP inhibitors.
Platinum-resistant disease remains largely incurable.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Access to HRD testing and PARP inhibitors outside high-income countries.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.
A milestone in how this cancer is treated.
OS 53.
PFS HR 0.
PFS HR 0.